Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.”In the company’s words, NCT06712407 on ClinicalTrials.gov
- Tested for
- IgA Nephropathy
- Main trialPhase 4
- “The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples taken * Have physical examinations done”In the company’s words, NCT06712407 on ClinicalTrials.gov
- Other names
- Budesonide modified released capsule · TARPEYO
- Copy of
- Tarpeyo (Calliditas)Tested side by side with the original in NCT06712407
Other drugs for IgA Nephropathy
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- SC0062Biocity Biopharmaceutics Co., Ltd. · Phase 3
- FelzartamabBiogen · Phase 3
- ZigakibartNovartis · Phase 3
- HRS-5965Hengrui · Phase 3
- IptacopanNovartis · Phase 3
Coming up1
- Mar 2027Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | Mar 2027 | Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | |
| Phase 3Completed | 10 Jul 2023 | Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy | |
| Phase 3Completed | 26 Feb 2024 | Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026